Arvind Manoharan1, Phillip M Short, William J Anderson, Brian J Lipworth. 1. Scottish Centre for Respiratory Research, Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee, DD1 9SY, Scotland, UK.
Abstract
INTRODUCTION: We performed a real-life retrospective analysis to assess the impact of long-acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on all-cause and cardiovascular mortality in patients with chronic obstructive pulmonary disease (COPD). METHODS: We used record linkage data from patients with a diagnosis of COPD in Tayside, Scotland, between 2001 and 2010. All-cause and cardiovascular mortality were assessed using Cox proportional hazard regression. RESULTS: A total of 4,133 patients were included, mean FEV1 of 59.5%, mean age of 68.9 years and mean follow-up of 4.6 years. There were 623 who were exposed to long-acting bronchodilators only and 3,510 to long-acting bronchodilators plus ICS. 1,372 patients (33%) died during the study period. Compared with controls taking only long-acting bronchodilators either alone or in combination, all-cause mortality was reduced in patients taking long-acting muscarinic antagonist (LAMA) + ICS as dual therapy: adjusted hazard ratio 0.62 (95% CI 0.45-0.85), but not by long-acting beta-agonist (LABA) + ICS: adjusted hazard ratio 1.02 (95% CI 0.80-1.31). Cardiovascular mortality was not reduced by dual therapy with either LABA or LAMA and concomitant ICS exposure. All-cause and cardiovascular mortality were both reduced in patients taking triple therapy with LABA + LAMA + ICS: adjusted hazard ratio 0.51 (95% CI 0.41-0.64) and 0.56 (95% CI 0.35-0.90), respectively. CONCLUSION: In patients exposed to ICS, concomitant use of LAMA alone as dual therapy or in combination with LABA as triple therapy were associated with reductions in all-cause mortality, while concomitant use of LABA without LAMA conferred no reduction. Moreover, only triple therapy was found to confer benefits on cardiovascular mortality.
INTRODUCTION: We performed a real-life retrospective analysis to assess the impact of long-acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on all-cause and cardiovascular mortality in patients with chronic obstructive pulmonary disease (COPD). METHODS: We used record linkage data from patients with a diagnosis of COPD in Tayside, Scotland, between 2001 and 2010. All-cause and cardiovascular mortality were assessed using Cox proportional hazard regression. RESULTS: A total of 4,133 patients were included, mean FEV1 of 59.5%, mean age of 68.9 years and mean follow-up of 4.6 years. There were 623 who were exposed to long-acting bronchodilators only and 3,510 to long-acting bronchodilators plus ICS. 1,372 patients (33%) died during the study period. Compared with controls taking only long-acting bronchodilators either alone or in combination, all-cause mortality was reduced in patients taking long-acting muscarinic antagonist (LAMA) + ICS as dual therapy: adjusted hazard ratio 0.62 (95% CI 0.45-0.85), but not by long-acting beta-agonist (LABA) + ICS: adjusted hazard ratio 1.02 (95% CI 0.80-1.31). Cardiovascular mortality was not reduced by dual therapy with either LABA or LAMA and concomitant ICS exposure. All-cause and cardiovascular mortality were both reduced in patients taking triple therapy with LABA + LAMA + ICS: adjusted hazard ratio 0.51 (95% CI 0.41-0.64) and 0.56 (95% CI 0.35-0.90), respectively. CONCLUSION: In patients exposed to ICS, concomitant use of LAMA alone as dual therapy or in combination with LABA as triple therapy were associated with reductions in all-cause mortality, while concomitant use of LABA without LAMA conferred no reduction. Moreover, only triple therapy was found to confer benefits on cardiovascular mortality.
Authors: Robert A Wise; Antonio Anzueto; Daniel Cotton; Ronald Dahl; Theresa Devins; Bernd Disse; Daniel Dusser; Elizabeth Joseph; Sabine Kattenbeck; Michael Koenen-Bergmann; Gordon Pledger; Peter Calverley Journal: N Engl J Med Date: 2013-08-30 Impact factor: 91.245
Authors: Philip M Short; Peter A Williamson; Douglas H J Elder; Samuel I W Lipworth; Stuart Schembri; Brian J Lipworth Journal: Chest Date: 2011-07-28 Impact factor: 9.410
Authors: Andrea Gershon; Ruth Croxford; Andrew Calzavara; Teresa To; Matthew B Stanbrook; Ross Upshur; Thérèse A Stukel Journal: JAMA Intern Med Date: 2013-07-08 Impact factor: 21.873
Authors: Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer Journal: N Engl J Med Date: 2008-10-05 Impact factor: 91.245
Authors: Christer Janson; Kjell Larsson; Karin H Lisspers; Björn Ställberg; Georgios Stratelis; Helena Goike; Leif Jörgensen; Gunnar Johansson Journal: BMJ Date: 2013-05-29
Authors: J M Hohlfeld; A Sharma; J A van Noord; P J G Cornelissen; E Derom; L Towse; V Peterkin; B Disse Journal: J Clin Pharmacol Date: 2013-11-27 Impact factor: 3.126